Home > Resources > Whitepapers > Polymers for Drug-Device Combination Products

Polymers for Drug-Device Combination Products

January 28, 2019

A wide variety of polymer types are available to the DDCP developer,
and many are available on the market that meet the necessary
regulatory requirements. Careful consideration should be given to
the choice of vendor to ensure that quality and consistency are
met. The available polymers span a wide range of physical properties
and are amenable to fabrication into devices using a variety of
processes. API can be readily incorporated into these polymers using
melt-mixing or solution processing. If product developers use
contract services for development or manufacturing, it is advisable to
select partners with a breadth of experience and a solid track record.

I'm For Real

Enter your details once to access all our information and resources

 

Spotlight

PDI, Inc.

PDI is a leading healthcare commercialization company providing superior insight-driven, integrated multi-channel message delivery for established and emerging healthcare companies. The company is dedicated to: -Providing outsourced sales and marketing expertise -Creating innovative digital and multi-channel promotional solutions -Enhancing engagement with health care practitioners -Optimizing clients’ commercial investments -Providing clients with strategic flexibility -Delivering full product commercialization services Founded in 1988, PDI was one of the first contract sales organizations (CSOs) in the United States. Today, PDI is reshaping the way pharmaceutical, biotech, medical device, and diagnostics companies reach and engage customers, commercialize products, and manage their portfolios.

OTHER WHITEPAPERS
news image

Considerations for migrating a drug product presentation from vial to pre-filled syringe

whitePaper | December 9, 2022

There is an upward trend for pharmaceutical companies to ask their contract development and manufacturing organisations (CDMO) to support the conversion.

Read More
news image

Overcoming Pharma’s Launch Performance Problem

whitePaper | March 24, 2023

The prescription medicine market recovered from the wild swings of the early pandemic with renewed volume growth, driven by generics. COVID-19 vaccines and treatments have created a substantial market.

Read More
news image

The Globalization Of The Pharmaceutical Industry

whitePaper | July 7, 2023

Rapid globalization has brought both opportunity and challenges for the pharmaceutical industry. Established healthcare markets are placing increased demands on industry to ensure products are beneficial, safe and available for patients and to improve how information is shared.

Read More
news image

New Active Substances Launched During 2021

whitePaper | June 27, 2022

Following on from our review of trends in the current pharmaceutical R&D pipeline this supplement takes a look at the industry’s success stories of 2021

Read More
news image

Asia Pacific – Clinical trial landscape

whitePaper | November 8, 2022

The Asia-Pacific region has emerged as a clinical trial hub due to the ease of regulatory compliance, low trial costs, rising patient population, and the availability of top clinical institutions.

Read More
news image

Ultrasafe film Ultra-high barrier Product stability Patient safety

whitePaper | December 22, 2022

Every viable pharmaceutical packaging system must comprise materials proven to protect its contents against moisture and other atmospheric variables, and be safe for use with the specified dosage form and the route of administration1

Read More

Considerations for migrating a drug product presentation from vial to pre-filled syringe

whitePaper | December 9, 2022

There is an upward trend for pharmaceutical companies to ask their contract development and manufacturing organisations (CDMO) to support the conversion.

Read More

Overcoming Pharma’s Launch Performance Problem

whitePaper | March 24, 2023

The prescription medicine market recovered from the wild swings of the early pandemic with renewed volume growth, driven by generics. COVID-19 vaccines and treatments have created a substantial market.

Read More

The Globalization Of The Pharmaceutical Industry

whitePaper | July 7, 2023

Rapid globalization has brought both opportunity and challenges for the pharmaceutical industry. Established healthcare markets are placing increased demands on industry to ensure products are beneficial, safe and available for patients and to improve how information is shared.

Read More

New Active Substances Launched During 2021

whitePaper | June 27, 2022

Following on from our review of trends in the current pharmaceutical R&D pipeline this supplement takes a look at the industry’s success stories of 2021

Read More

Asia Pacific – Clinical trial landscape

whitePaper | November 8, 2022

The Asia-Pacific region has emerged as a clinical trial hub due to the ease of regulatory compliance, low trial costs, rising patient population, and the availability of top clinical institutions.

Read More

Ultrasafe film Ultra-high barrier Product stability Patient safety

whitePaper | December 22, 2022

Every viable pharmaceutical packaging system must comprise materials proven to protect its contents against moisture and other atmospheric variables, and be safe for use with the specified dosage form and the route of
administration1

Read More
More Whitepapers

Spotlight

PDI, Inc.

PDI is a leading healthcare commercialization company providing superior insight-driven, integrated multi-channel message delivery for established and emerging healthcare companies. The company is dedicated to: -Providing outsourced sales and marketing expertise -Creating innovative digital and multi-channel promotional solutions -Enhancing engagement with health care practitioners -Optimizing clients’ commercial investments -Providing clients with strategic flexibility -Delivering full product commercialization services Founded in 1988, PDI was one of the first contract sales organizations (CSOs) in the United States. Today, PDI is reshaping the way pharmaceutical, biotech, medical device, and diagnostics companies reach and engage customers, commercialize products, and manage their portfolios.

Events